US 2006/0051353 A1 · Methods and compositions to evaluate antibody treatment response

Abstract

The present invention relates to methods and compositions to evaluate or assess the response of a subject to particular therapeutic treatment. More particularly, the invention provides methods to determine the response of subjects, or to adapt the treatment protocol of subjects treated with therapeutic antibodies. The invention is based on a determination of the FCGR3A genotype of a subject. The invention can be used for patients with malignancies, particularly lymphoma, and is suited to select best responders and/or adjust treatment condition or protocol for low responders.

Claims17

Dependent claims

A method of improving the efficacy or treatment condition or protocol of Crohn's disease comprising the steps of:

a) determining the FCGR3A158 genotype of a subject;
b) determining C-reactive protein (CRP) levels in a subject;
and
c) administering an anti-TNFα antibody to said subject if the subject is exhibits elevated levels of CRP and is homozygous for valine at position 158 of the FcγRIIIa receptor.

1 more element

Dependencies are inferred from the claim text.

Facts

Application

11/128,551Filed 13 May 2005

Priority

14 May 2004

Published

9 Mar 2006

Term ends

Not estimatedThe source records don’t support an estimate.

Classification11 codes

C12Q 1/6883
Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes: for diseases caused by alterations of genetic material
C07K 16/241
Against cytokines, lymphokines or interferons: tumor Necrosis Factors
A61K 2039/505
Medicinal preparations containing antigens or antibodies: comprising antibodies
C07K 2317/24
Characterized by taxonomic origin: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Methods and compositions to evaluate antibody treatment response

Life of this patent

Methods and compositions to evaluate antibody treatment response

Life of this patent

Abstract

Claims17